Home World News A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable... World News A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 845 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 The Frontline Oncology Workforce Unites to Reduce the Burden of Cancer... September 9, 2022 Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... April 9, 2025 ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 Load more HOT NEWS Joining the dots: How our new research data strategy will unlock... EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp Will This Cancer Metastasize? Check Its “Stickiness” Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated...
